Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016–2020 Compared to 2011–2015: Results From the ATLAS Surveillance Study
Journal of the Pediatric Infectious Diseases Society · 2023
DOI: 10.1093/jpids/piad055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2023. Verfasst von Qiwen Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy o…. Hauptthemen laut MEDLINE: Amikacin, Ascomycota. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Antimicrobial resistance (AMR) data in the pediatric population are limited, particularly in developing countries. This study assessed the AMR profile and key resistance phenotypes and genotypes for Gram-negative bacteria (GNB) isolates collected as part of the Antimicrobial Testing Leadership and Surveillance program from pediatric patients in Latin America, Africa-Middle East, and Asia in 2016–2020 versus 2011–2015.
Methods
Minimum inhibitory concentrations by broth microdilution methodology were interpreted per the Clinical and Laboratory Standards Institute. European Committee on Antimicrobial Susceptibility Testing breakpoints were used for interpreting colistin activity. β-lactamase genes were screened by polymerase chain reaction and sequencing.
Results
For Acinetobacter baumannii, low susceptibility (<60.0%) was observed for all antimicrobials, except colistin (≥92.9%), across regions and year periods. Ceftazidime-avibactam, amikacin, colistin, and meropenem were mostly active (78.6%–100.0%) against Enterobacter cloacae, Escherichia coli, and Klebsiella pneumoniae. For Pseudomonas aeruginosa, susceptibility to ceftazidime-avibactam, amikacin, and colistin was ≥85.9%. Among resistance phenotypes, carbapenem-resistant (CR, ≥44.8%) and difficult-to-treat resistant (DTR, ≥37.1%) rates were the highest in A. baumannii. A consistent increase in CR and DTR K. pneumoniae was noted across regions over time. Extended-spectrum β-lactamases (ESBL)-producing K. pneumoniae (32.6%–55.6%) were more frequent than ESBL-producing E. coli (25.3%–37.1%). CTX-M was the dominant ESBL among Enterobacterales. NDM-positive Enterobacterales species and VIM-positive P. aeruginosa were identified across regions.
Conclusions
This study identified high susceptibility to few agents for key GNB in pediatric patients. Continued surveillance of resistance phenotypes and genotypes at regional levels may help to guide appropriate treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Pfizer Ltd., Mumbai, India.
- Pfizer Inc., New York, New York, USA.
- Pfizer Latin America, Mexico, Mexico.
- Pfizer Emerging Asia Region, Taipei, Taiwan.
- Pfizer Ltd., Shanghai, China.
ORCID-Profile: Qiwen Yang
Förderung
- Pfizer
Zitieren
APA
Yang, Q., Kamat, S., Mohamed, N., Valdez, R. R., Lin, S., Su, M., Quintana, A., Kiratisin, P., Rodríguez-Zulueta, A. P., & Brink, A. (2023). Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016–2020 Compared to 2011–2015: Results From the ATLAS Surveillance Study. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piad055
Vancouver
Yang Q, Kamat S, Mohamed N, Valdez RR, Lin S, Su M, et al. Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016–2020 Compared to 2011–2015: Results From the ATLAS Surveillance Study. Journal of the Pediatric Infectious Diseases Society. 2023. doi:10.1093/jpids/piad055
BibTeX
@article{Yang2023,
author = {Yang, Qiwen and Kamat, Shweta and Mohamed, Naglaa and Valdez, Rafael Ricardo and Lin, Stephen and Su, Ming and Quintana, Alvaro and Kiratisin, Pattarachai and Rodríguez-Zulueta, Ana Patricia and Brink, Adrian},
title = {Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016–2020 Compared to 2011–2015: Results From the ATLAS Surveillance Study},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2023},
doi = {10.1093/jpids/piad055}
}
EUVIMED